LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/People In The News/Dale Binke New VP at AlloSource
People In The News

Dale Binke New VP at AlloSource

May 1, 2012 1 min read Premium comments

Advertisement

Dale Binke New VP at AlloSource
Dale Binke

AlloSource, of Centennial, Colorado, a non-profit provider of skin, bone and soft tissue allografts, has hired medical device veteran Dale Binke as the firm’s Vice President of Sales and Marketing. Binke has held senior leadership roles with Medtronic, Inc., Orthofix Interntional NV, Trinity Orthopedics and Spinal Elements, Inc. 

“I am excited to use my experience for such a passionate, mission-driven company that is truly guided by an internal compass, ” said Binke. “AlloSource’s progressive innovation has the potential to help medical professionals heal many patients.”

Kevin Cmunt, AlloSource executive vice president, said in the April 23 press release, “Dale’s experience in the medical device industry makes him essential to the AlloSource team as it continues to add new distribution resources.  With the sophistication of our new cellular tissue allografts, his senior leadership will help us position ourselves in the marketplace to ensure we honor the gift of donation by allowing it to help as many recipients as possible, ”

AlloSource offers more than 200 types of bone, skin, soft-tissue and custom-machined allografts for use in medical procedures and, according to company officials, is the world’s largest processor of cellular bone growth substitutes.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy